Skip to main content
. 2012 Sep 17;7:158. doi: 10.1186/1748-717X-7-158

Table 1.

Patient and tumor characteristics for IG-IMRT (n = 49) and RP followed by IMRT (n = 49)

Characteristics
Total
RP + IMRT
IG-IMRT
p-value
  (n = 98) (n = 49) (n = 49)  
Median age – years [range]
66.8 [51.7-82.7]
64.8 [51.7-82.7]
70.2 [53.3-82.4]
< 0.001 £
Median follow-up – months [range]
56.6 [18.22-115.1]
51.5 [18.2-115.1]
62.2 [25.5-106.0]
Clinical T stage
1.0 $
T1c – n (%)
60 (61.2%)
30 (61.2%)
30 (61.2%)
T2 – n (%)
4 (4.1%)
2 (4.1%)
2 (4.1%)
T2a – n (%)
14 (14.3%)
7 (14.3%)
7 (14.3%)
T2b – n (%)
20 (20.4%)
10 (20.4%)
10 (20.4%)
Gleason score on biopsy
1.0 μ
≤ 6 – n (%)
58 (59.2%)
29 (59.2%)
29 (59.2%)
7 – n (%)
40 (40.8%)
20 (40.8%)
20 (40.8%)
Pretherapeutic PSA
0.632 #
Median value – ng/mL [range]
8.7 [1.7 - 32]
8.7 [2.7 - 29]
8.7 [1.7 - 32]
Risk group
1.0 $
Low
30 (30.6%)
15 (30.6%)
15 (30.6%)
Intermediate
62 (63.3%)
31 (63.3%)
31 (63.3%)
High
6 (6.1%)
3 (6.1%)
3 (6.1%)
Concomitant hormones with radiation
1.0 μ
n (%)
20 (20.4%)
10 (20.4%)
10 (20.4%)
Adjuvant hormones with radiation
0.564 μ
n (%)
14 (14.3%)
6 (12.2%)
8 (16.3%)
Mean dose of radiotherapy
Prostatic fossa – median value (Gy) [range]
70.0 [31.4 – 79.8]
66.0 [31.4 – 70.3]
77.4 [73.0 – 79.8]
< 0.001 #
Rectum – median value (Gy) [range]
38.1 [4.8 – 61.1]
36.0 [4.8 – 57.1]
39.3 [26.5 – 61.1]
0.061 #
Bladder – median value (Gy) [range] 32.7 [15.5 – 67.3] 43.6 [16.8 – 63.7] 31.3 [15.5 – 67.3] < 0.001 £

* Union for International Cancer Control classification 2002 (6th edition); £ Student’s test; $ Fisher’s exact test; # Kruskall Wallis test; μ: Chi2.

IG-IMRT: Image-guided intensity modulated radiotherapy; RP: radical prostatectomy, PSA: Prostate Specific Antigen.